中文

Home>Biolake

Biolake holds Q1 supply chain match-making meeting

Updated: 2024-03-13 (chinaopticsvalley.com) Weibo Weixin Qzone Facebook Twitter More

光谷.jpg

The quarterly industrial supply chain match-making conference for OVC-based Biolake takes place on March 12. [Photo/WeChat account of Optics Valley of China]

On March 12, Biolake in the East Lake High-tech Development Zone (also known as the Optics Valley of China, or OVC) held a quarterly industrial supply chain match-making conference, where it signed a batch of key investment projects and key supply chain projects.

Over 200 guests from the upstream and downstream of the life and health industry attended the event. This includes representatives from leading enterprises in the chain, platform enterprises, supporting enterprises, financial institutions, and medical institutions.

At the event, 12 future industries and key supply chain enterprises signed collaboration contracts with the Wuhan National Biological Industrial Base Service Center, with the cumulative contract amount reaching 16.65 billion yuan ($2.32 billion). These projects focus on innovation in cutting-edge areas such as artificial organs, innovative stem cell drugs, organs-on-chips, functional proteins, and semiconductor laser therapy. All of these projects aim to accelerate the formation of new productive forces.

Biolake appointed 12 local entrepreneurs as investment promotion ambassadors.

Additionally, Biolake signed a strategic cooperation agreement with the Bank of China in order to fully optimize its business environment and utilize financial support to attract investment.

The conference also released the supply and demand information of the life and health industrial chain in the Wuhan metropolitan area, and established the Wuhan metropolitan area regional coordinated development alliance for the industry.

After 15 years of development, OVC has built a life and health industrial ecosystem in the fields of biomedicine, medical devices, and bio-agriculture. There are currently over 400 new drugs undergoing research and development and over 1,400 certified second and third-class medical devices in the valley.